

R. Hayes

#3

CRF Errors Corrected by the STIC Systems Branch

Serial Number: 09/620,840C

CRF Processing Date: 9/18/2002  
Edited by: [signature]  
Verified by: [signature] (STIC staff)

ENTERED

- ☐ Changed a file from non-ASCII to ASCII
- ☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.
- ☐ Edited a format error in the Current Application Data section, specifically: \_\_\_\_\_
- ☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other \_\_\_\_\_
- ☐ Added the mandatory heading and subheadings for "Current Application Data".
- ☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.
- ☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically: \_\_\_\_\_
- ☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were: \_\_\_\_\_
- ☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited: \_\_\_\_\_
- ☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
- ☐ Inserted colons after headings/subheadings. Headings edited included: \_\_\_\_\_
- ☐ Deleted extra, invalid, headings used by an applicant, specifically: \_\_\_\_\_
- ☐ Deleted: ☐ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as \_\_\_\_\_
- ☐ Inserted mandatory headings, specifically: \_\_\_\_\_
- ☐ Corrected an obvious error in the response, specifically: \_\_\_\_\_
- ☐ Edited identifiers where upper case is used but lower case is required, or vice versa.
- ☐ Corrected an error in the Number of Sequences field, specifically: \_\_\_\_\_
- ☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
- ☐ Deleted **ending** stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: \_\_\_\_\_
- ☒ Other: corrected misspelling of "properties" in sequence 1

09/620840

Application No.: \_\_\_\_\_

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 16:31:27

Input Set : A:\2885.app

Output Set: N:\CRF4\09182002\I620840C.raw

**Does Not Comply  
Corrected Diskette Needed**

```

3 <110> APPLICANT: STEWARD, LANCE E
4     HERRINGTON, TODD M
5     AOKI, KEI R
7 <120> TITLE OF INVENTION: LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS
9 <130> FILE REFERENCE: leucine motif/BoNT
11 <140> CURRENT APPLICATION NUMBER: 09/620,840C
12 <141> CURRENT FILING DATE: 2000-07-21
14 <160> NUMBER OF SEQ ID NOS: 18
16 <170> SOFTWARE: PatentIn Ver. 2.1
18 <210> SEQ ID NO: 1
19 <211> LENGTH: 7
20 <212> TYPE: PRT
21 <213> ORGANISM: Artificial Sequence
23 <220> FEATURE:
24 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
25     properties substantially similar to that of
26     leucine based sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: X may be any amino acid or derivatives thereof
31 <400> SEQUENCE: 1
W--> 32 Xaa Asp Xaa Xaa Xaa Leu Leu
33     1             5
36 <210> SEQ ID NO: 2
37 <211> LENGTH: 7
38 <212> TYPE: PRT
39 <213> ORGANISM: Artificial Sequence
41 <220> FEATURE:
42 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
43     properties substantially similar to leucine based
44     motif
46 <220> FEATURE:
47 <223> OTHER INFORMATION: X may be any amino acid or derivatives thereof
49 <400> SEQUENCE: 2
W--> 50 Xaa Glu Xaa Xaa Xaa Leu Leu
51     1             5
54 <210> SEQ ID NO: 3
55 <211> LENGTH: 7
56 <212> TYPE: PRT
57 <213> ORGANISM: Artificial Sequence
59 <220> FEATURE:
60 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
61     properties substantially similar to that of
62     leucine based motif

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 16:31:27

Input Set : A:\2885.app

Output Set: N:\CRF4\09182002\I620840C.raw

```

64 <220> FEATURE:
65 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
67 <400> SEQUENCE: 3
W--> 68 Xaa Asp Xaa Xaa Xaa Leu Ile
69   1           5
72 <210> SEQ ID NO: 4
73 <211> LENGTH: 7
74 <212> TYPE: PRT
75 <213> ORGANISM: Artificial Sequence
77 <220> FEATURE:
78 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
79   properties substantially similar to that of
80   leucine based motif
82 <220> FEATURE:
83 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
85 <400> SEQUENCE: 4
W--> 86 Xaa Asp Xaa Xaa Xaa Leu Met
87   1           5
90 <210> SEQ ID NO: 5
91 <211> LENGTH: 7
92 <212> TYPE: PRT
93 <213> ORGANISM: Artificial Sequence
95 <220> FEATURE:
96 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
97   properties substantially similar to that of
98   leucine based motif
100 <220> FEATURE:
101 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
103 <400> SEQUENCE: 5
W--> 104 Xaa Glu Xaa Xaa Xaa Leu Ile
105   1           5
108 <210> SEQ ID NO: 6
109 <211> LENGTH: 7
110 <212> TYPE: PRT
111 <213> ORGANISM: Artificial Sequence
113 <220> FEATURE:
114 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
115   properties substantially similar to leucine based
116   motif
118 <220> FEATURE:
119 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
121 <400> SEQUENCE: 6
W--> 122 Xaa Glu Xaa Xaa Xaa Leu Met
123   1           5
126 <210> SEQ ID NO: 7
127 <211> LENGTH: 7
128 <212> TYPE: PRT
129 <213> ORGANISM: botulinum toxin type A
131 <400> SEQUENCE: 7

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 16:31:27

Input Set : A:\2885.app

Output Set: N:\CRF4\09182002\I620840C.raw

132 Phe Glu Phe Tyr Lys Leu Leu  
133 1 5  
136 <210> SEQ ID NO: 8  
137 <211> LENGTH: 7  
138 <212> TYPE: PRT  
139 <213> ORGANISM: rat  
141 <220> FEATURE:  
142 <223> OTHER INFORMATION: This fragment is commonly known as Rat VMAT 1.  
144 <300> PUBLICATION INFORMATION:  
145 <301> AUTHORS: Liu, et al  
146 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
147 the regulation of synaptic transmission  
148 <303> JOURNAL: Trends in Cell Biology  
149 <304> VOLUME: 9  
150 <306> PAGES: 356-363  
151 <307> DATE: SEP-1999  
153 <400> SEQUENCE: 8  
154 Glu Glu Lys Arg Ala Ile Leu  
155 1 5  
158 <210> SEQ ID NO: 9  
159 <211> LENGTH: 7  
160 <212> TYPE: PRT  
161 <213> ORGANISM: rat  
163 <220> FEATURE:  
164 <223> OTHER INFORMATION: This fragment is commonly known as Rat VMAT 2.  
166 <300> PUBLICATION INFORMATION:  
167 <301> AUTHORS: Liu, et al  
168 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
169 the regulation of synaptic transmission  
170 <303> JOURNAL: Trends in Cell Biology  
171 <304> VOLUME: 9  
172 <306> PAGES: 356-363  
173 <307> DATE: SEP-1999  
175 <400> SEQUENCE: 9  
176 Glu Glu Lys Met Ala Ile Leu  
177 1 5  
180 <210> SEQ ID NO: 10  
181 <211> LENGTH: 7  
182 <212> TYPE: PRT  
183 <213> ORGANISM: rat  
185 <220> FEATURE:  
186 <223> OTHER INFORMATION: This fragment is known as Rat VACHT  
188 <220> FEATURE:  
189 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
191 <300> PUBLICATION INFORMATION:  
192 <301> AUTHORS: Liu, et al  
193 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
194 the regulation of synaptic transmission  
195 <303> JOURNAL: Trends in Cell Biology

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 16:31:27

Input Set : A:\2885.app

Output Set: N:\CRF4\09182002\I620840C.raw

196 <304> VOLUME: 9  
197 <306> PAGES: 356-363  
198 <307> DATE: SEP-1999  
200 <400> SEQUENCE: 10  
201 Ser Glu Arg Asp Val Leu Leu  
202 1 5  
205 <210> SEQ ID NO: 11  
206 <211> LENGTH: 7  
207 <212> TYPE: PRT  
208 <213> ORGANISM: rat  
210 <220> FEATURE:  
211 <223> OTHER INFORMATION: This fragment is known as Rat (delta).  
213 <400> SEQUENCE: 11  
214 Val Asp Thr Gln Val Leu Leu  
215 1 5  
218 <210> SEQ ID NO: 12  
219 <211> LENGTH: 7  
220 <212> TYPE: PRT  
221 <213> ORGANISM: mouse  
223 <220> FEATURE:  
224 <223> OTHER INFORMATION: This fragment is also known as "mouse (delta)".  
226 <400> SEQUENCE: 12  
227 Ala Glu Val Gln Ala Leu Leu  
228 1 5  
231 <210> SEQ ID NO: 13  
232 <211> LENGTH: 7  
233 <212> TYPE: PRT  
234 <213> ORGANISM: frog  
236 <220> FEATURE:  
237 <223> OTHER INFORMATION: This fragment is known as "frog (gamma/delta)"  
239 <220> FEATURE:  
240 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
242 <400> SEQUENCE: 13  
243 Ser Asp Lys Gln Asn Leu Leu  
244 1 5  
247 <210> SEQ ID NO: 14  
248 <211> LENGTH: 7  
249 <212> TYPE: PRT  
250 <213> ORGANISM: chicken  
252 <220> FEATURE:  
253 <223> OTHER INFORMATION: This fragment is also known as "chicken  
254 (gamma/delta)".  
256 <220> FEATURE:  
257 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
259 <400> SEQUENCE: 14  
260 Ser Asp Arg Gln Asn Leu Ile  
261 1 5  
264 <210> SEQ ID NO: 15  
265 <211> LENGTH: 7

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 16:31:27

Input Set : A:\2885.app

Output Set: N:\CRF4\09182002\I620840C.raw

266 <212> TYPE: PRT  
267 <213> ORGANISM: sheep  
269 <220> FEATURE:  
270 <223> OTHER INFORMATION: This fragment is known as "Sheep (delta)".  
272 <400> SEQUENCE: 15  
273 Ala Asp Thr Gln Val Leu Met  
274 1 5  
277 <210> SEQ ID NO: 16  
278 <211> LENGTH: 7  
279 <212> TYPE: PRT  
280 <213> ORGANISM: human  
282 <220> FEATURE:  
283 <223> OTHER INFORMATION: This fragment is known as "Human CD3(delta)".  
285 <220> FEATURE:  
286 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
288 <300> PUBLICATION INFORMATION:  
289 <301> AUTHORS: Liu, et al  
290 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
291 the regulation of synaptic transmission  
292 <303> JOURNAL: Trends in Cell Biology  
293 <304> VOLUME: 9  
294 <306> PAGES: 356-363  
295 <307> DATE: SEP-1999  
297 <400> SEQUENCE: 16  
298 Ser Asp Lys Gln Thr Leu Leu  
299 1 5  
302 <210> SEQ ID NO: 17  
303 <211> LENGTH: 7  
304 <212> TYPE: PRT  
305 <213> ORGANISM: human  
307 <220> FEATURE:  
308 <223> OTHER INFORMATION: This fragment is known as "Human CD4"  
310 <220> FEATURE:  
311 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
313 <300> PUBLICATION INFORMATION:  
314 <301> AUTHORS: Liu, et al  
315 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
316 the regulation of synaptic transmission  
317 <303> JOURNAL: Trends in Cell Biology  
318 <304> VOLUME: 9  
319 <306> PAGES: 356-363  
320 <307> DATE: SEP-1999  
322 <400> SEQUENCE: 17  
323 Ser Gln Ile Lys Arg Leu Leu  
324 1 5  
327 <210> SEQ ID NO: 18  
328 <211> LENGTH: 7  
329 <212> TYPE: PRT  
330 <213> ORGANISM: human

RAW SEQUENCE LISTING ERROR SUMMARY      DATE: 09/18/2002  
PATENT APPLICATION:    US/09/620,840C      TIME: 16:31:28

Input Set : A:\2885.app  
Output Set: N:\CRF4\09182002\I620840C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,3,4,5  
Seq#:2; Xaa Pos. 1,3,4,5  
Seq#:3; Xaa Pos. 1,3,4,5  
Seq#:4; Xaa Pos. 1,3,4,5  
Seq#:5; Xaa Pos. 1,3,4,5  
Seq#:6; Xaa Pos. 1,3,4,5



VARIABLE LOCATION SUMMARY

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 16:31:28

Input Set : A:\2885.app

Output Set: N:\CRF4\09182002\I620840C.raw

Use of n's or Xaa's (NEW RULES):

Use of n's and/or Xaa's have been detected in the Sequence Listing.

Use of <220> to <223> is MANDATORY if n's or Xaa's are present.

in <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

Seq#:1; Xaa Pos. 1,3,4,5

Seq#:2; Xaa Pos. 1,3,4,5

Seq#:3; Xaa Pos. 1,3,4,5

Seq#:4; Xaa Pos. 1,3,4,5

Seq#:5; Xaa Pos. 1,3,4,5

Seq#:6; Xaa Pos. 1,3,4,5

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 16:31:28

Input Set : A:\2885.app

Output Set: N:\CRF4\09182002\I620840C.raw

L:32 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:1  
L:32 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:1  
L:32 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0  
L:50 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:2  
L:50 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:2  
L:50 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0  
L:68 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:3  
L:68 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:3  
L:68 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0  
L:86 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:4  
L:86 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:4  
L:86 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0  
L:104 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:5  
L:104 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:5  
L:104 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0  
L:122 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:6  
L:122 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:6  
L:122 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0



1600

## RAW SEQUENCE LISTING

DATE: 09/18/2002

PATENT APPLICATION: US/09/620,840C

TIME: 17:06:13

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\09182002\I620840C.raw

```

3 <110> APPLICANT: STEWARD, LANCE E
4     HERRINGTON, TODD M
5     AOKI, KEI R
7 <120> TITLE OF INVENTION: LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS
9 <130> FILE REFERENCE: leucine motif/BoNT
11 <140> CURRENT APPLICATION NUMBER: 09/620,840C
12 <141> CURRENT FILING DATE: 2000-07-21
14 <160> NUMBER OF SEQ ID NOS: 18
16 <170> SOFTWARE: PatentIn Ver. 2.1
18 <210> SEQ ID NO: 1
19 <211> LENGTH: 7
20 <212> TYPE: PRT
21 <213> ORGANISM: Artificial Sequence
23 <220> FEATURE:
24 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
25     properties substantially similar to that of
26     leucine based sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: X may be any amino acid or derivatives thereof
31 <400> SEQUENCE: 1
W--> 32 Xaa Asp Xaa Xaa Xaa Leu Leu
33     1             5
36 <210> SEQ ID NO: 2
37 <211> LENGTH: 7
38 <212> TYPE: PRT
39 <213> ORGANISM: Artificial Sequence
41 <220> FEATURE:
42 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
43     properties substantially similar to leucine based
44     motif
46 <220> FEATURE:
47 <223> OTHER INFORMATION: X may be any amino acid or derivatives thereof
49 <400> SEQUENCE: 2
W--> 50 Xaa Glu Xaa Xaa Xaa Leu Leu
51     1             5
54 <210> SEQ ID NO: 3
55 <211> LENGTH: 7
56 <212> TYPE: PRT
57 <213> ORGANISM: Artificial Sequence
59 <220> FEATURE:
60 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
61     properties substantially similar to that of
62     leucine based motif

```

## RAW SEQUENCE LISTING

DATE: 09/18/2002

PATENT APPLICATION: US/09/620,840C

TIME: 17:06:13

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\09182002\I620840C.raw

```

64 <220> FEATURE:
65 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
67 <400> SEQUENCE: 3
W--> 68 Xaa Asp Xaa Xaa Xaa Leu Ile
69   1           5
72 <210> SEQ ID NO: 4
73 <211> LENGTH: 7
74 <212> TYPE: PRT
75 <213> ORGANISM: Artificial Sequence
77 <220> FEATURE:
78 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
79     properties substantially similar to that of
80     leucine based motif
82 <220> FEATURE:
83 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
85 <400> SEQUENCE: 4
W--> 86 Xaa Asp Xaa Xaa Xaa Leu Met
87   1           5
90 <210> SEQ ID NO: 5
91 <211> LENGTH: 7
92 <212> TYPE: PRT
93 <213> ORGANISM: Artificial Sequence
95 <220> FEATURE:
96 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
97     properties substantially similar to that of
98     leucine based motif
100 <220> FEATURE:
101 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
103 <400> SEQUENCE: 5
W--> 104 Xaa Glu Xaa Xaa Xaa Leu Ile
105   1           5
108 <210> SEQ ID NO: 6
109 <211> LENGTH: 7
110 <212> TYPE: PRT
111 <213> ORGANISM: Artificial Sequence
113 <220> FEATURE:
114 <223> OTHER INFORMATION: Description of Artificial Sequence:fragment having
115     properties substantially similar to leucine based
116     motif
118 <220> FEATURE:
119 <223> OTHER INFORMATION: X may be any amino acid or derivative thereof
121 <400> SEQUENCE: 6
W--> 122 Xaa Glu Xaa Xaa Xaa Leu Met
123   1           5
126 <210> SEQ ID NO: 7
127 <211> LENGTH: 7
128 <212> TYPE: PRT
129 <213> ORGANISM: botulinum toxin type A
131 <400> SEQUENCE: 7

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 17:06:13

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\09182002\I620840C.raw

132 Phe Glu Phe Tyr Lys Leu Leu  
133 1 5  
136 <210> SEQ ID NO: 8  
137 <211> LENGTH: 7  
138 <212> TYPE: PRT  
139 <213> ORGANISM: rat  
141 <220> FEATURE:  
142 <223> OTHER INFORMATION: This fragment is commonly known as Rat VMAT 1.  
144 <300> PUBLICATION INFORMATION:  
145 <301> AUTHORS: Liu, et al  
146 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
147 the regulation of synaptic transmission  
148 <303> JOURNAL: Trends in Cell Biology  
149 <304> VOLUME: 9  
150 <306> PAGES: 356-363  
151 <307> DATE: SEP-1999  
153 <400> SEQUENCE: 8  
154 Glu Glu Lys Arg Ala Ile Leu  
155 1 5  
158 <210> SEQ ID NO: 9  
159 <211> LENGTH: 7  
160 <212> TYPE: PRT  
161 <213> ORGANISM: rat  
163 <220> FEATURE:  
164 <223> OTHER INFORMATION: This fragment is commonly known as Rat VMAT 2.  
166 <300> PUBLICATION INFORMATION:  
167 <301> AUTHORS: Liu, et al  
168 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
169 the regulation of synaptic transmission  
170 <303> JOURNAL: Trends in Cell Biology  
171 <304> VOLUME: 9  
172 <306> PAGES: 356-363  
173 <307> DATE: SEP-1999  
175 <400> SEQUENCE: 9  
176 Glu Glu Lys Met Ala Ile Leu  
177 1 5  
180 <210> SEQ ID NO: 10  
181 <211> LENGTH: 7  
182 <212> TYPE: PRT  
183 <213> ORGANISM: rat  
185 <220> FEATURE:  
186 <223> OTHER INFORMATION: This fragment is known as Rat VACHT  
188 <220> FEATURE:  
189 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
191 <300> PUBLICATION INFORMATION:  
192 <301> AUTHORS: Liu, et al  
193 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
194 the regulation of synaptic transmission  
195 <303> JOURNAL: Trends in Cell Biology

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 17:06:14

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\09182002\I620840C.raw

196 <304> VOLUME: 9  
197 <306> PAGES: 356-363  
198 <307> DATE: SEP-1999  
200 <400> SEQUENCE: 10  
201 Ser Glu Arg Asp Val Leu Leu  
202    1                   5  
205 <210> SEQ ID NO: 11  
206 <211> LENGTH: 7  
207 <212> TYPE: PRT  
208 <213> ORGANISM: rat  
210 <220> FEATURE:  
211 <223> OTHER INFORMATION: This fragment is known as Rat (delta).  
213 <400> SEQUENCE: 11  
214 Val Asp Thr Gln Val Leu Leu  
215    1                   5  
218 <210> SEQ ID NO: 12  
219 <211> LENGTH: 7  
220 <212> TYPE: PRT  
221 <213> ORGANISM: mouse  
223 <220> FEATURE:  
224 <223> OTHER INFORMATION: This fragment is also known as "mouse (delta)."  
226 <400> SEQUENCE: 12  
227 Ala Glu Val Gln Ala Leu Leu  
228    1                   5  
231 <210> SEQ ID NO: 13  
232 <211> LENGTH: 7  
233 <212> TYPE: PRT  
234 <213> ORGANISM: frog  
236 <220> FEATURE:  
237 <223> OTHER INFORMATION: This fragment is known as "frog (gamma/delta)"  
239 <220> FEATURE:  
240 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
242 <400> SEQUENCE: 13  
243 Ser Asp Lys Gln Asn Leu Leu  
244    1                   5  
247 <210> SEQ ID NO: 14  
248 <211> LENGTH: 7  
249 <212> TYPE: PRT  
250 <213> ORGANISM: chicken  
252 <220> FEATURE:  
253 <223> OTHER INFORMATION: This fragment is also known as "chicken  
254       (gamma/delta)."  
256 <220> FEATURE:  
257 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
259 <400> SEQUENCE: 14  
260 Ser Asp Arg Gln Asn Leu Ile  
261    1                   5  
264 <210> SEQ ID NO: 15  
265 <211> LENGTH: 7

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/620,840C

DATE: 09/18/2002

TIME: 17:06:14

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\09182002\I620840C.raw

266 <212> TYPE: PRT  
 267 <213> ORGANISM: sheep  
 269 <220> FEATURE:  
 270 <223> OTHER INFORMATION: This fragment is known as "Sheep (delta)."  
 272 <400> SEQUENCE: 15  
 273 Ala Asp Thr Gln Val Leu Met  
 274 1 5  
 277 <210> SEQ ID NO: 16  
 278 <211> LENGTH: 7  
 279 <212> TYPE: PRT  
 280 <213> ORGANISM: human  
 282 <220> FEATURE:  
 283 <223> OTHER INFORMATION: This fragment is known as "Human CD3(delta)."  
 285 <220> FEATURE:  
 286 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
 288 <300> PUBLICATION INFORMATION:  
 289 <301> AUTHORS: Liu, et al  
 290 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
 291 the regulation of synaptic transmission  
 292 <303> JOURNAL: Trends in Cell Biology  
 293 <304> VOLUME: 9  
 294 <306> PAGES: 356-363  
 295 <307> DATE: SEP-1999  
 297 <400> SEQUENCE: 16  
 298 Ser Asp Lys Gln Thr Leu Leu  
 299 1 5  
 302 <210> SEQ ID NO: 17  
 303 <211> LENGTH: 7  
 304 <212> TYPE: PRT  
 305 <213> ORGANISM: human  
 307 <220> FEATURE:  
 308 <223> OTHER INFORMATION: This fragment is known as "Human CD4"  
 310 <220> FEATURE:  
 311 <223> OTHER INFORMATION: The serine at position 1 may be phosphorylated.  
 313 <300> PUBLICATION INFORMATION:  
 314 <301> AUTHORS: Liu, et al  
 315 <302> TITLE: Membrane trafficking of neurotransmitter transporter in  
 316 the regulation of synaptic transmission  
 317 <303> JOURNAL: Trends in Cell Biology  
 318 <304> VOLUME: 9  
 319 <306> PAGES: 356-363  
 320 <307> DATE: SEP-1999  
 322 <400> SEQUENCE: 17  
 323 Ser Gln Ile Lys Arg Leu Leu  
 324 1 5  
 327 <210> SEQ ID NO: 18  
 328 <211> LENGTH: 7  
 329 <212> TYPE: PRT  
 330 <213> ORGANISM: human

RAW SEQUENCE LISTING ERROR SUMMARY      DATE: 09/18/2002  
PATENT APPLICATION: US/09/620,840C      TIME: 17:06:15

Input Set : A:\PTO.AMC.txt  
Output Set: N:\CRF4\09182002\I620840C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,3,4,5  
Seq#:2; Xaa Pos. 1,3,4,5  
Seq#:3; Xaa Pos. 1,3,4,5  
Seq#:4; Xaa Pos. 1,3,4,5  
Seq#:5; Xaa Pos. 1,3,4,5  
Seq#:6; Xaa Pos. 1,3,4,5